MonoSol Rx signs agreement with Hikma for thin film products in the Middle East

Published: 18-Dec-2008
Regulatory Research & Development

MonoSol Rx has entered into an agreement for thin film pharmaceutical products with Hikma Pharmaceutical, a manufacturer of generic and in-licensed pharmaceutical products.


MonoSol Rx has entered into an agreement for thin film pharmaceutical products with Hikma Pharmaceutical, a manufacturer of generic and in-licensed pharmaceutical products.

MonoSol Rx is the developer of PharmFilm technology and a drug delivery company specialising in dissolving thin film pharmaceutical products.

Under terms of the agreement, Hikma will exclusively distribute in the Middle East three products based on PharmFilm technology. Hikma will obtain all registrations and approvals required to market the products throughout the region.

MonoSol Rx will receive milestone payments and payments for the purchase of product supply.

Mark Schobel, president and chief executive of MonoSol Rx, said: "In addition to expanding our reach into new geographic territories, our partnership with Hikma further validates our proprietary PharmFilm technology, leadership in thin film drug development, and growing intellectual property portfolio."

  • Companies:
  • Hikma Pharmaceuticals
  • MonoSol Rx
See more

You may also like

Regulatory

Status update on ANDA for generic Advair Diskus (VR315 [US])

Read more
Vectura Group, an industry leading inhalation CDMO, confirms the announcement made by its partner Hikma Pharmaceuticals

Trending Articles

  1. IMed Consultancy enabling innovation in the mental healthcare sector with Limbic Limbic is a London-based start-up that is using world-leading, clinically validated Artificial Intelligence and beautiful product design to make psychological therapy accessible for everyone, everywhere
  2. AstraZeneca and Amgen's Tezspire meets primary endpoints in Phase III trial The Phase III WAYPOINT trial demonstrated Tezspire's ability to reduce nasal polyps and congestion compared to placebo when administered subcutaneously
  3. Autolus Therapeutics' CAR-T therapy, Aucatzyl, bags FDA approval for ALL Aucatzyl (obecabtagene autoleucel) is the first CAR-T therapy to receive FDA approval with no risk evaluation mitigation strategy requirement
  4. Navigating regulatory challenges in pharmaceutical packaging: lessons from the past and strategies for the future To safeguard drug efficacy, maintain strict quality standards and ensure patient safety, pharmaceutical packaging is subject to a wide range of regulations around the world, reports Kun Shing Chan, Director of QA at Tjoapack
  5. Dissolution of an immediate release nanoparticle formulation using the NanoDis system An efficient dissolution method to aid in nanoparticle drug development

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Regulatory

Status update on ANDA for generic Advair Diskus (VR315 [US])

Vectura Group, an industry leading inhalation CDMO, confirms the announcement made by its partner Hikma Pharmaceuticals
Regulatory

Hikma launches Dalfampridine Extended-release tablets

Hikma Pharmaceuticals, formerly known as West-Ward Pharmaceuticals, has launched Dalfampridine Extended-release tablets, 10 mg, the generic therapeutic equivalent to Ampyra
Regulatory

Hikma enters settlement agreement with Jazz for sodium oxybate

Jazz will grant Hikma and West-Ward the right to sell an authorised generic of Xyrem in the US
Research & Development

Blood cancer charity thanks Hikma Pharmaceuticals for its support

DKMS is dedicated to the fight against blood cancer, recruiting stem cell donors and providing second chances at life
Manufacturing

Hikma announces successful resolution to FDA warning letter at its Portugal facility

Will enable Hikma to accelerate the introduction of new products to the market
Regulatory

Hikma receives warning letter from US FDA

Over environmental monitoring issues at its plant in Portugal
Research & Development

MidaSol Therapeutics signs research collaboration with major US pharmaceutical company

Midatech and MonoSol Rx joint venture to develop new treatment for diabetes
Subscribe now